PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma

This study is testing PIN (a drug injected directly into tumors) combined with an anti-PD1 immunotherapy drug in patients with advanced or metastatic liver cancer (hepatocellular carcinoma or HCC) that has stopped responding to or cannot tolerate standard treatments. **You may be eligible if...** - You are between 18 and 75 years old with confirmed advanced or metastatic liver cancer (HCC) - Your cancer has progressed after or you cannot tolerate standard treatments (targeted therapy and immunotherapy) - You have at least one tumor that can be injected directly (at least 10 mm in size) - Your liver function, blood counts, and organ function are within acceptable limits - You have chronic hepatitis B and are on antiviral therapy (if applicable) **You may NOT be eligible if...** - You have significant liver cirrhosis with loss of liver function (Child-Pugh score above 7) - You have uncontrolled fluid in the abdomen (ascites) - You have active autoimmune disease requiring systemic treatment - You have had significant heart problems or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.